FIGURE 2. GSK's preferential pricing commitments to the developing world

From the following article:

GlaxoSmithKline & malaria

Nature 415, 716(7 February 2002)

doi:10.1038/415716a

BACK TO ARTICLE


filled circle Sustainable, preferential prices for all GSK HIV/AIDS medicines

filled circle Anti-malarial medicines also offered at sustainable, preferential prices

filled circle Expansion of countries eligible for preferential pricing offers. The offer will apply to all Least Developed Countries (as defined by the UN) and all countries of sub-Saharan Africa – a total of 63 countries

filled circle Expansion of customer groups eligible for preferential pricing offers, including the Global Fund to Fight AIDS, TB and Malaria

filled circle Development of a pilot programme to assess the impact of preferentially priced anti-infectives and de-worming agents in resource-poor settings.

Figures & Tables index
BACK TO ARTICLE